Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
复制标题
DOI：
10.2174/0929867323666160406121117
复制
发表时间：
2016-01-01
影响因子：
4.1
通讯作者：
Schwartz, David E.
中科院分区：
文献类型：
--
作者：
Chong, Zhao Zhong;Changyaleket, Benjarat;Schwartz, David E.
钙结合蛋白S100 B作为多种疾病的生物标志物引起了人们的极大关注。S100 B主要在胶质细胞中表达，通过细胞内和细胞外信号通路发挥作用。S100 B的生物学作用与其浓度和生理状态密切相关。S100 B的释放可以与晚期糖基化终产物受体结合，并诱导多种细胞信号转导的启动。S100 B生物活性的调节已被认为是通过磷酸肌醇3激酶/Akt、p53、促分裂原活化蛋白激酶、转录因子（包括核因子-κ B和环磷酸腺苷）来实现的。血液中S100 B的水平可用于预测多种疾病的进展或预后，如脑血管疾病、神经退行性疾病、运动神经元疾病、创伤性脑损伤、精神分裂症、抑郁症、糖尿病、心肌梗死、癌症和感染性疾病。鉴于S100 B的活性与这些疾病的病理过程有关，S100 B不应被简单地视为生物标志物，它也可能作为这些疾病的治疗靶点。进一步阐明S100 B的作用可能为多种疾病制定创新的治疗策略。
The calcium binding protein S100B has attracted great attention as a biomarker for a variety of diseases. S100B is mainly expressed in glial cells and functions through intracellular and extracellular signaling pathways. The biological roles of S100B have been closely associated with its concentrations and its physiological states. The released S100B can bind to the receptor of advanced glycation end products and induce the initiation of multiple cell signaling transductions. The regulation of S100B bioactivities has been suggested through phosphoinositide 3 kinase/Akt, p53, mitogen-activated protein kinases, transcriptional factors including nuclear factor-kappaB, and cyclic adenosine monophosphate. The levels of S100B in the blood may function to predict the progress or the prognosis of many kinds of diseases, such as cerebrovascular diseases, neurodegenerative diseases, motor neuron diseases, traumatic brain injury, schizophrenia, depression, diabetes mellitus, myocardial infarction, cancer, and infectious diseases. Given that the activity of S100B has been implicated in the pathological process of these diseases, S100B should not be simply regarded as a biomarker, it may also function as therapeutic target for these diseases. Further elucidation of the roles of S100B may formulate innovative therapeutic strategies for multiple diseases.